RHUPH20

Thrombosis: Has been reported to occur following treatment with IG products, including HYQVIA and in the absence of known risk factors. In patients at risk, administer at the minimum dose and infusion rate practicable. Ensure adequate hydration before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity... HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]. See Safety Info Thrombosis Warning in Full Prescribing Info.